According to filings with the U.S. Securities and Exchange Commission, SynDevRx is raising up to $29,354,820.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Brad Carver played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SynDevRx
Metabo-oncology which focuses on the link between cancer and metabolic hormone dysfunction is poised to spark a leap forward in cancer patient treatment. Cancer and systemic metabolic hormones (e.g., insulin, leptin) caused by overweight, diabetes, or pre-diabetes are closely linked. Yet, this condition that affects millions of cancer patients is being overlooked as the major contributor to cancer progression that it is. Whats worse, many anti-cancer treatments cause metabolic dysfunction which can limit drug effectiveness and even lead to treatment resistance. SynDevRx the leader in the emerging field of metabo-oncology is tackling this urgent and unmet medical need with its clinical drug evexomostat (SDX-7320). Weve advanced our lead compound from discovery and early chemistry through patenting and through a recently-completed Phase 1 dose escalation safety trial at costs well below the industry norm. The SynDevRx team includes an impressive roster of well-known clinical oncologists, leaders in academic research, professors from premier institutions and experienced drug development professionals. Many came here with direct, hands-on research and clinical experience with fumagillin-based MetAP2 inhibitors.

To learn more about SynDevRx, visit http://syndevrx.com/
SynDevRx Linkedin Page: https://www.linkedin.com/company/syndevrx-inc./

Contact:
Brad Carver, President and Chief Executive Officer
617-401-3110
http://www.linkedin.com/in/brad-carver-a487523

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.